Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Evolus, Inc. stock logo
EOLS
Evolus
$9.27
+0.7%
$10.02
$8.67
$17.82
$593.82M0.97754,518 shs424,231 shs
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
$0.00
$0.00
$0.00
$0.02
$9K0.7913,056 shs104 shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.26
-0.8%
$1.40
$1.12
$2.55
$62.29M0.436,314 shs68,347 shs
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
$0.31
$0.30
$0.22
$1.14
$53.51M0.931.01 million shs2.68 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Evolus, Inc. stock logo
EOLS
Evolus
+0.65%-0.43%-6.93%-13.28%-15.65%
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00%0.00%-75.00%0.00%+150.00%
MediciNova, Inc. stock logo
MNOV
MediciNova
-0.79%-3.08%-10.64%+1.61%-10.00%
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Evolus, Inc. stock logo
EOLS
Evolus
3.6182 of 5 stars
3.50.00.03.50.63.30.6
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
1.8783 of 5 stars
3.82.00.00.00.00.80.0
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Evolus, Inc. stock logo
EOLS
Evolus
3.00
Buy$23.75156.20% Upside
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00
N/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
3.50
Strong Buy$7.00455.56% Upside
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MNOV, EVLO, EOLS, and TYME Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
MediciNova, Inc. stock logo
MNOV
MediciNova
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy ➝ Strong-Buy$6.00 ➝ $5.00
5/8/2025
Evolus, Inc. stock logo
EOLS
Evolus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
4/17/2025
Evolus, Inc. stock logo
EOLS
Evolus
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$21.00
4/10/2025
Evolus, Inc. stock logo
EOLS
Evolus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
4/9/2025
Evolus, Inc. stock logo
EOLS
Evolus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
4/9/2025
MediciNova, Inc. stock logo
MNOV
MediciNova
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Evolus, Inc. stock logo
EOLS
Evolus
$266.27M2.24N/AN/A$0.09 per share103.00
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
$1M61.80N/AN/A$1.07 per share1.18
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
N/AN/AN/AN/A$0.47 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Evolus, Inc. stock logo
EOLS
Evolus
-$50.42M-$0.89N/AN/AN/A-20.40%-759.04%-20.14%7/30/2025 (Estimated)
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
-$114.53MN/A0.00N/AN/AN/AN/A7/7/2025 (Estimated)
MediciNova, Inc. stock logo
MNOV
MediciNova
-$11.04M-$0.23N/AN/AN/AN/A-20.77%-19.68%8/6/2025 (Estimated)
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
-$23.63M-$0.14N/AN/AN/A-28.30%-26.21%N/A

Latest MNOV, EVLO, EOLS, and TYME Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Evolus, Inc. stock logo
EOLS
Evolus
-$0.09N/AN/AN/A$82.18 millionN/A
5/13/2025Q1 2025
MediciNova, Inc. stock logo
MNOV
MediciNova
-$0.14-$0.06+$0.08-$0.06N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Evolus, Inc. stock logo
EOLS
Evolus
N/AN/AN/AN/AN/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
N/AN/AN/AN/AN/A
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Evolus, Inc. stock logo
EOLS
Evolus
22.00
2.34
2.16
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
N/A
17.66
17.66
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
N/A
14.06
14.06

Institutional Ownership

CompanyInstitutional Ownership
Evolus, Inc. stock logo
EOLS
Evolus
90.69%
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.31%
MediciNova, Inc. stock logo
MNOV
MediciNova
9.90%
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
16.69%

Insider Ownership

CompanyInsider Ownership
Evolus, Inc. stock logo
EOLS
Evolus
5.90%
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
1.02%
MediciNova, Inc. stock logo
MNOV
MediciNova
13.60%
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
16.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Evolus, Inc. stock logo
EOLS
Evolus
17064.48 million60.67 millionOptionable
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
12018.98 million18.79 millionNo Data
MediciNova, Inc. stock logo
MNOV
MediciNova
1049.05 million42.38 millionOptionable
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
17172.21 million143.10 millionOptionable

Recent News About These Companies

How Nubank’s Investment in Tyme Helps African Startups
TymeBank parent valued at $1.5-billion in latest fundraise
Brazilian fintech giant invests in SA-born Tyme Group
Multi-billion funding bolsters Tyme Group valuation
Best Restaurants in Leominster, Massachusetts
Best Restaurants in Quincy, Illinois
Best Restaurants in Peoria, Illinois

New MarketBeat Followers Over Time

Media Sentiment Over Time

Evolus stock logo

Evolus NASDAQ:EOLS

$9.27 +0.06 (+0.65%)
As of 07/3/2025 02:38 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Evelo Biosciences stock logo

Evelo Biosciences NASDAQ:EVLO

$0.0005 0.00 (0.00%)
As of 07/2/2025 02:56 PM Eastern

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

MediciNova stock logo

MediciNova NASDAQ:MNOV

$1.26 -0.01 (-0.79%)
As of 07/3/2025 01:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

Tyme Technologies stock logo

Tyme Technologies NASDAQ:TYME

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.